Clinical Trials on Uterovaginal Prolapse in Japan

Total 6 results

Kyushu University

Recruiting

Clinical Trial of GAIA-102 for Refractory/Relapse Neuroblastomas and Other Malignant Pediatric Solid Tumors

Pediatric Solid Tumors | Refractory/Relapse Neuroblastoma

Japan
Ibtihal Altalhi

Unknown

Effectiveness of Mobile Phone-Based Intervention to Prevent Smoking Relapse Among Recent Smoking Quitters

Smoking Cessation

Saudi Arabia
National University Hospital, Singapore
Celgene; International Myeloma Foundation

Unknown

Pomalidomide-Cyclophosphamide-Dexamethasone (PCD) Versus Pomalidomide-Dexamethasone (PD) in Relapse or Refractory Myeloma

Relapse Multiple Myeloma

Singapore, Hong Kong, Japan, Korea, Republic of, Taiwan
GAIA BioMedicine Inc.

Recruiting

Clinical Trial of GAIA-102 for Advanced and Relapse NSCLC

NSCLC | Cell Therapy

Japan
Novartis Pharmaceuticals

Completed

Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Japanese Patients With Relapsed/Refractory Multiple Myeloma

Relapse/Refractory Multiple Myeloma

Japan
Eisai Inc.

Completed

A Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Participants With Low CA125 Platinum-sensitive Ovarian Cancer

Platinum-Sensitive Ovarian Cancer in First Relapse

United States, Italy, United Kingdom, Germany, Spain, Belgium, Japan

3

Subscribe